Oral oncolytic and antiretroviral therapy administration: dose adjustments, drug interactions, and other considerations for clinical use

The rise in non-AIDS defining cancers (NADCs) is emerging as a leading cause of death for HIV and cancer patients. To address this, current literature and guidelines suggest the continuation of antiretroviral therapy (ART) with oral oncolytic agents to prevent adverse complications associated with H...

Descripción completa

Detalles Bibliográficos
Autores principales: Badowski, Melissa E, Burton, Bradley, Shaeer, Kristy M, Dicristofano, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383448/
https://www.ncbi.nlm.nih.gov/pubmed/30815023
http://dx.doi.org/10.7573/dic.212550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383448/
https://www.ncbi.nlm.nih.gov/pubmed/30815023
http://dx.doi.org/10.7573/dic.212550

Ejemplares similares